Business
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications
Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF)...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant ApplicationsCalgary, Alberta--(Newsfile Corp. - August 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it incorporated Hemostemix Quebec Inc. and has applied for grant funding of $6 Million, to locate production of ACP-01 in Montreal. \"We are moving production of ACP-01 to Quebec, as have negotitated terms for a possible shared site where we can co-locate our staff to produce a treatment for clinical trials at 1/10th the cost of contract manufacturers,\" stated Thomas Smeenk, CEO. \"We also have drafted a phase II heart (ischemic cardiomyopathy) clinical trial protocol, which will be submitted to regulators shortly. With the grants, we will build out production, and our patented automated cell therapy system (ACTS), to generate revenue from the sale of ACP-01 as an exemption approved compassionate treatment for critical limb ischemia, while completing phase II-III clinical trials,\" Smeenk said. ABOUT HEMOSTEMIXHemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. For more information, please visit www.hemostemix.com.For further information, please contact: Thomas Smeenk, President, CEO & Co-FounderEM: [email protected] PH: 905-580-4170Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains \"forward-looking information\" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: financing of the Company and its lead product ACP-01, the Phase II Clinical Trial of ischemic cardiomyopathy and related results, the retrospective study of ischemic and dilated cardiomyopathy, and the commercialization of ACP-...